PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
PTC Therapeutics (PTCT) Misses Q3 EPS by 22c
November 2, 2017 5:03 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($0.82), $0.22 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $41.85 million versus the consensus estimate of $45.03 million.
2017 Guidance:
Translarna net sales guidance for 2017 is anticipated to be between $120 and $140 million. We... More